Structural insights into the unique recognition module between α-synuclein peptide and nanobody.

Area of Science:

• Structural Biology
• Protein Engineering
• Neuroscience

Background:

• Nanobodies are antibody fragments with unique properties for biological applications.
• Alpha-synuclein (αSyn) aggregation is a hallmark of Parkinson's disease.
• Understanding protein-nanobody interactions is crucial for developing targeted therapies.

Purpose of the Study:

• To elucidate the crystal structure of nanobody Nbα-syn01 bound to an αSyn peptide.
• To investigate the molecular basis of this unique nanobody-αSyn interaction.
• To explore structure-guided engineering of nanobodies for enhanced therapeutic potential.

Main Methods:

• X-ray crystallography to determine the complex structure of Nbα-syn01 and αSyn peptide.
• Structure-guided truncation of Nbα-syn01.
• Binding affinity assays and α-synuclein aggregation inhibition studies.

Main Results:

• The crystal structure revealed a unique binding mode where the αSyn peptide replaces the nanobody's N-terminal region.
• Recognition is primarily mediated by main chain interactions, with specificity in the central αSyn peptide region (48-52).
• Structure-guided truncation led to tighter binding and improved inhibition of α-synuclein aggregation.

Conclusions:

• The study uncovers a novel nanobody recognition mechanism for α-synuclein.
• This provides a molecular explanation for enhanced binding affinity.
• Findings offer a framework for engineering nanobodies as improved diagnostic and therapeutic tools for Parkinson's disease.